FDA declines to approve Shin Nippon Biomedical's migraine drug

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 18, 2024 at 11:12: AM
via The U.S. health regulator has declined to approve Japan-based Shin Nippon Biomedical Laboratories' (2395.T) treatment for acute migraine late on Wednesday, citing manufacturing concerns.

article source
 

<



Similar threads

cafead
FDA declines to approve Regeneron&#039;s blood cancer therapy
Replies
0
Views
30
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA declines to approve Merck-Daiichi&#039;s &#039;guided missile&#039; cancer drug
Replies
0
Views
24
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA declines to approve Astellas&#039; gastric cancer drug
Replies
0
Views
195
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Immunitybio slumps as FDA declines to approve bladder cancer treatment
Replies
0
Views
107
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA declines to approve Eli Lilly&#039;s bowel disease drug
Replies
0
Views
270
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote